The stock of Masimo Corporation (NASDAQ:MASI) hit a new 52-week high and has $76.88 target or 24.00% above today’s $62.00 share price. The 7 months bullish chart indicates low risk for the $3.14B company. The 1-year high was reported on Nov, 17 by Barchart.com. If the $76.88 price target is reached, the company will be worth $753.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 181,469 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 43.66% since April 15, 2016 and is uptrending. It has outperformed by 39.04% the S&P500.
Masimo Corporation (NASDAQ:MASI) Ratings Coverage
Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was downgraded by Raymond James to “Outperform” on Wednesday, January 6. The firm has “Buy” rating given on Wednesday, August 5 by TH Capital.
According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”
Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.47, from 0.85 in 2016Q1. The ratio improved, as 14 funds sold all Masimo Corporation shares owned while 85 reduced positions. 52 funds bought stakes while 79 increased positions. They now own 38.69 million shares or 0.37% less from 38.84 million shares in 2016Q1.
Deutsche Bancorp Ag last reported 341,454 shares in the company. Federated Inc Pa accumulated 57,668 shares or 0.01% of the stock. Brown Advisory Incorporated has invested 0% of its portfolio in Masimo Corporation (NASDAQ:MASI). Gemmer Asset Management Limited Liability reported 173 shares or 0% of all its holdings. Grt Cap Prtn Lc has invested 0.17% of its portfolio in Masimo Corporation (NASDAQ:MASI). Invesco owns 194,860 shares or 0% of their US portfolio. Raymond James Services Advisors last reported 7,188 shares in the company. Turner Ltd Partnership accumulated 22,000 shares or 0.36% of the stock. Gamco Investors Et Al holds 130,200 shares or 0.05% of its portfolio. Janus Capital Ltd Limited Liability Company last reported 2.78 million shares in the company. Renaissance Technologies Ltd Com last reported 143,800 shares in the company. Tudor Invest Corp Et Al, a Connecticut-based fund reported 13,464 shares. The Connecticut-based Matarin Mngmt Ltd has invested 0% in Masimo Corporation (NASDAQ:MASI). Sawgrass Asset Management Limited Liability has 18,920 shares for 0.05% of their US portfolio. Morgan Stanley holds 0.01% or 286,220 shares in its portfolio.
Insider Transactions: Since May 24, 2016, the stock had 0 buys, and 27 insider sales for $29.33 million net activity. 5,000 shares were sold by Van Ramshorst David J, worth $262,500 on Thursday, June 30. 2,000 Masimo Corporation (NASDAQ:MASI) shares with value of $119,167 were sold by FITCH SANFORD. The insider KIANI JOE E sold $5.10M. On Thursday, August 4 the insider Jansen Paul sold $588,800. McClenahan Thomas Samuel also sold $590,000 worth of Masimo Corporation (NASDAQ:MASI) shares. 40,000 shares were sold by de Raad Mark, worth $1.98 million. Shares for $3.58M were sold by Sampath Anand.
MASI Company Profile
Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.